Monoclonal antibodyPhase 3 trialInvestigational
Tafasitamab
How it works
Binds the CD19 receptor on B cells, marking them for destruction by the immune system.
Cancer types
Leukemia— CD19-positive
Efficacy
In clinical trials, around 40% of CD19-positive patients achieved a complete or partial response, with a median progression-free survival of approximately 6 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.